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INTRODUCTION 
 
The dengue virus belongs to the genus Flavivirus, family 
Flaviviridae Aedea (Stegomyia) aegypti is the principal vector of dengue 
viruses. 
Oneof the most severe arthropod borne viral diseases in terms of 
human mortality and morbidity is Dengue fever . The major cause of 
mortality is DHF/ DSS. Multiple reasons for abnormal haemostasis are 
vascular endothelial damage. Thrombopahty and coagulation 
abnormalities. Abnormalities in the coagulation and inflammation systems 
in dengue fever have been documented in various studies. The imbalance 
between coagulation and fibrinolysis serve as prognostic markers 
Dengue virus infection spectrum spreads from an undifferentiated 
fever and dengue fever (DF) to dengue haemorrhagic fever (DHF) with 
shock and expanded dengue syndrome1. The hallmark of DHF is plasma 
leakage which   may lead to shock. Both DF and DHF could have bleeding 
manifestations. Derangement of activated partial thromboplastin time 
(APTT) and the international normalised ratio (INR) is attributed to 
multiple factors. 
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This derangement  in the coagulation system may be extrinsic or 
intrinsic which can be demonstrated by doing PT, and aPTT . Mortality can 
be reduced if these values can be determined and predicted to have been 
prolonged. These investigations aren’t costly too . Thus a study was done 
on the coagulation profile of patients admitted with dengue fever and 
correlation with severity was undertaken. 
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AIMS AND OBJECTIVES 
 
• To assess the liver enzyme and coagulation profile alterations among 
dengue  patients . 
• To follow up   dengue patients over a period of 10 days and asses 
the progression of disease. 
• To asses correlation between the abnormal lab parameters and their 
significance as early predictors of fluid leakage and bleeding 
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REVIEW OF LITERATURE 
 
DENGUE EPIDEMIOLOGY 
One of  the most rapidly spreading mosquito-borne viral disease in 
the world in Dengue. In the last 50 years, incidence has increased 30-fold 
with increasing geographic expansion to new countries and, in the present 
decade, from urban to rural settings (Figure 1.1). An estimated 50 million 
dengue infections occur annually (Figure 1.2) and approximately 2.5 
billion people live in dengue endemic countries (1). The 2002 World 
Health Assembly resolution WHA55.17 (2) urged greater commitment to 
dengue by WHO and its Member States. Of particular significance is the 
2005 World Health Assembly resolution WHA58.3 on the revision of the 
International Health Regulations (IHR) (3), which includes dengue as an 
example of a disease that may constitute a public health emergency of 
international concern with implications for health security due to 
disruption and rapid epidemic spread beyond national borders. 
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National scenario  
Dengue virus was isolated in India for the first time in 1945. The 
first evidence of occurrence of dengue fever in the country was reported in 
1956 from Vellore district in Tamil Nadu.  Calcutta (West Bengal) saw the 
first dengue hemorrhagic fever (DHF) outbreak Of the 36 states/UTs, 35 
(all except Lakshadweep) have reported dengue cases during the last two 
decades. 
 
 
 
10.C 
 
 
10.C 
 
(As of 1 November 2008) 
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Recurring outbreaks of dengue fever(DF)/DHF have been reported 
from various states/ UTs—Andhra Pradesh, Chandigarh, Delhi, Goa, 
Haryana, Gujarat, Karnataka, Kerala, Maharashtra, Rajasthan, Uttar 
Pradesh, Puducherry, Punjab, Tamil Nadu and West Bengal. 
During 1996, one of the most severe outbreaks of DF/DHF occurred 
in Delhi, with 10 252 cases and 423 deaths being reported (country total 
being 16 517 cases and 545 deaths). In 2006, the country witnessed an 
outbreak of DF/DHF with 12 317 cases and 184 deaths. The incidence of 
dengue is increasing in the last few years. During 2010, a total of 28 292 
cases were reported, which increased to 50 222 in 2012 and 75 808 in 2013 
– the highest since 1991. The case fatality ratio (CFR – deaths per 100 
cases) has declined from 3.3% in 1996 to 0.4% in 2010 after the national 
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guidelines on clinical management of DF/DHF/dengue shock syndrome 
(DSS) were developed and circulated in 2007. This further declined to 
0.3% in 2013.7,8 
Dengue virus 
Dengue viruses, are categorized under the genus Flavivirus. These 
viruses contain single stranded RNA and are small in size (50 nm). Four 
dengue virus serotypes are designated as DENV-1, DENV-2, DENV-3 and 
DENV-4 .More than one serotype can be in circulation at a point of time.. 
Each offers cross protection only for a short period of time. Infection with 
any one serotype confers lifelong immunity to the virus serotype. 
Fig. 2. Seasonal trends of Dengue/DHF 2003-07 
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Cocirculation of virus is possible because this doesn’t offer 
protection in heteroantibodies. Individual variations occur in antibody 
responses to the dengue virus. Secondary infections are associated with 
elevated risks of severe disease outcomes. Primary and secondary 
infections are differentiated based on the antigenic responses. Superadded 
infection may cause worse infection , which is salient for dengue virus . 
All four serotypes are reported from India. 
The dengue virus genome is composed of three structural protein 
genes encoding the nucleocapsid of core protein ©, a membrane associated 
protein (M), an envelope protein and seven non-structural (NS) proteins – 
NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5.. NS1 protein interacts 
with immune system and  evokes T cell responses. NS1 protein  is utilized 
as a diagnostic marker of the infection 
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Dengue viral infection is mostly asymptomatic. The exact causes of 
severity among some patients when there is interaction between agent and 
host are still not clearly understood. Infected people play a major role in 
introducing the dengue virus by their movement to newer areas. 
Vector                         
  Aedes aegypti  
 
Aedes aegypti habitats may  be either terrestrial or aquatic which  
utilized tree holes and plant axils (leaf joints) found in forested areas as 
aquatic habitats historically. Adaptation of Aedes aegypti to urban domestic 
habitats have led to the exploitation of a range of artificial containers 
frequently associated with human habitation which include vases, water 
tanks and tyres. 
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The female Aedes aegypti feeds exclusively on humans and  
on a lower frequency of other hosts including bovine, swine, cat, rat, 
and chicken which represents <1% of bloodmeals  
 
Aedes mates singly or in pairs , this plasticity allows for easy 
propagation of the mosquito “Aggregation pheromone” along with the 
olfactory stimulus and the wing beat rarte of the female aedes mosquito 
attracts the male mosquito and swarming occurs followed by mating . 
 
Aedes aegypti is cited by the Global Invasive Species Database as 
the main vector in Yellow fever . cickungunya , west nile fever etc 
transmitted by Aedes aegypti together with the West Nile virus (European 
Centre for Disease Prevention and Control 2005-2015). 
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Control strategies are aimed at preventing mosquito bites, 
maintaining populations at “acceptable” densities, minimizing mosquito-
host contact and reducing the longevity of female mosquitoes. It 
incorporates the concept of vector and disease control. Personal 
protection involves the use of domestic insecticides, repellents (natural or 
synthetic), insecticide treated materials and paints. Control also 
incorporates both biological and chemical methods (Fig. 5).  
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Transmission cycle 
During a blood meal from an infected person Aedes gets affected 
and acquires the virus. Following an extrinsic incubation period of 8 to 10 
days, the mosquito becomes infected .The mosquito transmits the virus via 
the saliva which it injects to prevent coagulation .  The cycle of dengue 
continues by this process. Following an intrinsic incubation period of 4 to 
7 days (range 3–14 days) Dengue begins abruptly. There is also evidence 
of vertical transmission of dengue virus from infected female mosquitoes 
to the next generation. 
Vertical transmission and transmission by blood product transfusion 
have also been demonstrated. 
Host factor 
All ages  and sexes are susceptible to infection . Fever within a 
week of return from a dengue endemic ares is highly suggestive of 
dengue . persistence of fever after 2 week of return from an endemic area 
is not suggestive of Dengue. The geographical spread of dengue has been 
reported to occur mainly by people travelling from endemic areas to non-
endemic areas. 
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Genetic factors have been implicated in the occurrence of 
Dengue fever some are protective too. Certain HLA- class I and  class  
II alleles, polymorphisms in the tumor necrosis factor alpha(TNF-α),  
Vitamin  D receptor,18 CTLA-4 and transforming growth factor ß 
(TGF-β)19 have been shown to be associated with development of 
DHF/DSSSYMPTOMS: 
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Host immune factors responsible for severe disease: cross reactive 
antibodies 
 
Cross reactive T cells and antibodies are implicatedin the haphazard 
development of cytokine release and the exudation of fluid from th serosal 
surfaces , especially in secondary dengue syndrome . 
Collectively, all this evidence suggests that the pathogenesis of DHF 
is far more complex than previously thought. Therefore, more detailed 
studies in patients with acute severe dengue infection and asymptomatic 
infection should be carried out in order to try and understand this complex 
immunopathogenesis.  
15 
 
Dengue viral infected person may be asymptomatic or 
symptomatic and clinical manifestations vary from undifferentiated 
fever to florid haemorrhage and shock. The clinical presentations 
depend on various factors such as age, immune status of the host, the 
virus strain and primary or secondary infection. Infection with one 
dengue serotype gives lifelong immunity to that particular serotype. 
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Undifferentiated dengue Fever (UDF) 
The fever of dengue is similar to any other virla illness and is 
highly difficult to differentiate from others . There may or may not be 
a rash during fever or defervescence . The symptoms of DF may not 
be very distinguished and signs of bleeding or capillary leakage may 
be absent. 
Majority of the dengue virus infected persons are asymptomatic 
but symptomatic patients may present with undifferentiated fever, non-
severe and severe manifestation. Some patients with dengue virus 
infection present with severe manifestations like shock, plasma 
leakage, bleeding and organ involvement. Based on thrombocyte 
count, haematocrit, evidence of capillary leakage, bleeding and 
hypotension. DHF has been divided into four grades. 15(Refer 3.8) Non 
severe cases may be DF and DHF grade I and II without significant 
bleeding. Severe dengue may be DHF III and IV with or without 
significant bleeding . DHF grade I and II may be severe when they 
present with significant bleeding or with metabolic and electrolyte 
abnormalities. Sometimes DF may present with life threatening 
significant bleeding without evidence of capillary leakage or 
haemoconcentration. Some dengue Fever patients may also present 
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with multiple organ involvement without bleeding and shock. In some 
patient there may be unusual atypical presentation also. 
 Minor bleeding from different sites, scanty haemoptysis, 
haematemesis, haematuria, increase menstrual flow, gum bleeding, 
etc. 
 Abdominal pain or discomfort 
 Palpitation, breathlessness 
 Hepatic dysfunction or hepatomegaly 
 Decrease urinary output 
 High HCT (>45%) 
 Rapid fall in platelet count 
 Cold clammy extremities 
 Narrow pulse pressure 
 Rapid pulse 
 Hypotension 
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High Risk group 
The following high risk groups may have severe manifestations or 
complications with DF/DHF, therefore this group of patients should be 
closely monitored for the development of severity: 
• Pregnancy 
• Infant 
• Elderly 
• Obesity 
• Peptic ulcer diseases 
• G6PD deficiency 
• Thalassemia 
• Coronary Artery Disease 
• Chronic diseases: diabetes, COPD, bronchial asthma, hypertension 
• Patients on steroid, antiplatelet, anticoagulant drugs 
• HIV infected persons/ Immuno-compromised persons 
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Clinical Features of DF: 
An acute febrile illness of 2-7 days duration with two or more of 
the following manifestations: 
Headache, retro-orbital pain, myalgia, arthralgia, rash, 
haemorrhagic manifestations. 
 
Dengue Haemorrhagic Fever (DHF): 
a). A case with clinical criteria of dengue Fever plus 
b). Haemorrhagic tendencies evidenced by one or more of the 
following 
1. Positive tourniquet test 
2. Petechiae, ecchymoses or purpura 
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3. Bleeding from mucosa, gastrointestinal tract, injection sites Plus 
c). Thrombocytopenia (<100 000 cells per cumm) plus 
d). Evidence of plasma leakage due to increased vascular 
permeability, manifested by one or more of the following: 
1. A rise in average haematocrit for age and sex > 20% 
2. A more than 20% drop in haematocrit following volume 
replacement treatment compared to baseline 
3. Signs of plasma leakage (pleural effusion, ascites, 
hypoproteinemia) 
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Dengue Shock Syndrome (DSS): 
All the above criteria for DHF with evidence of circulatory failure 
manifested by rapid and weak pulse and narrow pulse pressure (< 20% 
mm Hg) or hypotension for age, cold and clammy skin and restlessness. 
 
 
Probable DF/DHF: 
A case compatible with clinical description (Clinical Criteria at 
3.3) of dengue Fever during outbreak.: 
OR 
Non-ELISA based NS1 antigen/ IgM positive. 
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(A positive test by RDT will be considered as probable due to 
poor sensitivity and Specificity of currently available RDTs.) 
Conifrmed dengue Fever: 
A case compatible with the clinical description of dengue fever 
with at least one of the following 
 Isolation of the dengue virus (Virus culture +VE) from serum, 
plasma, leucocytes. 
 Demonstration of IgM antibody titre by ELISA positive in single 
serum  
 Demonstration of dengue virus antigen in serum sample by NS1-
ELISA. 
 IgG seroconversion in paired sera after 2 weeks with Four fold 
increase of IgG titre. 
 Detection of viral nucleic acid by polymerase chain reaction 
(PCR). 
 
Natural course of dengue Infection 
The clinical course of illness passes through the following three 
phases: 
• Febrile phase 
• Critical phase 
• Convalescent phase 
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Febrile phase 
Fever is biphasic with an appearance of a rash in  the 2 to 7 th 
day associated with headache and nasal discharge . There may be pain 
in retro-orbital area, muscles, joint or bone. Fading rash is present 
during the 3rd to 5th day which is usually morbilliform and eruptive . 
Localized cluster of petechiae may appear over upper and lower 
limbs. Dengue Fever with unusual haemorrhagic manifestation may 
be seen rarely in case with co-morbid illness.  
Critical phase (Leakage phase) 3 to 4 days  after onset of fever  
DF/DHF patients usually go to critical phase. Plasma leakage and high 
haemoconcentration are documented during this critical phase and 
patients may develop hypotension. Shock, bleeding, accumulation of fluid 
in pleural and abdominal cavity are caused due to abnormal haemostasis 
and leakage of plasma. Various organ involvements and metabolic 
derangement causes High morbidity and mortality in DHF/DSS. This 
period of plasma leakage usually persists for 2 days . 
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Convalescent phase (recovery phase) 
The extracellular fluid returns to the circulatory system during 
the recovery phase and signs and symptoms improve. After 6-7 days of 
fever  one can expect this phase and  it last for 2-3 days. Longer 
convalescence may be expected in some of the patients with severe 
shock, organ involvement and other complications which may require 
specific treatment. Pulmonary oedema may commence  due to fluid 
overload if the fluid replacement is not optimized carefully. 
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Laboratory diagnosis 
 
Kinetics of dengue virus replication and host response 
By the time a person infected with dengue virus develops fever, 
the infection is widely disseminated. The virus is found in serum or 
plasma, in circulating blood cells and in selected tissues, especially 
those of the immune system, for approximately 2–7 days, roughly 
corresponding to the period of fever. 
In primary infection with dengue virus, serological tests may 
yield results that indicate a specific dengue serotype with specimens 
obtained early in the disease. In other cases, cross-reactive antibodies, 
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often apparent in the first 1– 2 months after infection, may confound 
determination of the serotype. In such cases, a monotypic antibody 
specific for the infecting serotype may be detected 3–6 months after 
infection. Therefore, specimens obtained during late conva- lescence 
from patients with a primary seroresponse pattern may be useful in 
determining the infecting dengue virus serotype. 
Collection and handling of specimens 
• Collect a specimen as soon as possible after the onset of illness, 
hospital admission or attendance at a clinic (this is called the acute 
serum, S1). 
• Collect a specimen shortly before discharge from the hospital or, in 
the event of a fatality, at the time of death (convalescent serum, S2). 
• Collect a third specimen, in the event hospital discharge occurs 
within 1–2 days of the subsidence of fever, 7–21 days after the acute 
serum was drawn (late convalescent serum, S3). 
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Specimen-collection procedures: tubes or vials 
•  Aseptically collect 2–5 ml or more of venous blood. 
• Use adhesive tape marked with pencil or indelible ink or a typewritten 
or printed self-adhesive label to identify the container. At a minimum, 
the name of the patient, the identification number and the date of 
collection should be indicated. 
• Use tubes or vials with screw-caps, if possible. Fix the cap with 
adhesive tape, wax or other sealing material to prevent leakage during 
transport. 
• If a specimen cannot be analysed or shipped within 24 hours of being 
drawn, the serum should be separated from the cells and stored frozen. 
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• Ship specimens for culture or serology on wet ice to a laboratory as 
soon as possible. 
Serological tests 
 
Haemagglutination-inhibition test 
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Dengue viruses agglutinate gander erythrocytes and those of certain other 
species as well as trypsinized type O human red blood cells. The HI test is based 
on the ability of dengue virus antibodies to inhibit this agglutination. The test is 
described in most virology manuals. 
 
Neutralization tests 
Although several neutralization tests have been described for 
dengue virus, the most sensitive and specific method is the serum 
dilution, virus-constant, plaque-reduction test. Following primary 
dengue infection, relatively specific neutralizing antibodies are detected 
in early convalescence.  
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Dot-blot immunoassay 
Dot-blot immunoassay technology is relatively new, and 
reagents and test procedures are evolving. At least one dot-blot 
immunoassay for dengue anti- bodies is available commercially. 
As greater interest develops among commer- cial manufacturers, 
additional dot-blot immunoassays are likely to enter the market. 
Complement-fixation test 
The complement-fixation test may also be used in serological 
diagnosis, al- though it is the least sensitive serological assay, and other 
assays have generally replaced this method. Complement-fixing antibody 
typically appears later than IgM or HI antibody and is usually more 
specific. Therefore, it can be useful in confirming dengue infection in 
patients with paired serum samples taken late in the infection. A fourfold 
rise in complement-fixing antibody, where the interval between the acute 
and convalescent serum is less than 2 weeks, signifies a secondary 
seroresponse pattern. 
Isolation of dengue virus 
Isolation of most strains of dengue virus from clinical specimens can 
be accomplished in the majority of cases, provided that the sample is taken 
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in the first five days of illness and processed without delay. Specimens that 
may be suitable for virus isolation include acute phase serum, plasma or 
washed buffy coat from the patient, autopsy tissues from fatal cases, 
especially liver, spleen, lymph nodes and thymus and mosquitoes collected 
in nature. Isolation of the virus takes 7–10 days, hence it may not be very 
useful for starting the management of patients with DF/DHF. 
NVBDCP-recommended tests for laboratory diagnosis 
–For confirmation of dengue infection, Government of India (GoI) 
recommends use of ELISA-based antigen detection test (NS1) for 
diagnosing the cases from the first day onwards and antibody detection test 
IgM capture ELISA (MAC-ELISA) for diagnosing the cases after the fifth 
day of onset of disease.19 
–Directorate of National Vector Borne Disease Control Programme 
(NVBDCP), GoI has identified a network of laboratories (sentinel 
surveillance hospitals and apex referral laboratories) for surveillance of 
dengue fever cases across the country since 2007. These laboratories are 
also meant to augment the diagnostic facilities in all endemic areas. They 
are linked with Apex Referral Laboratories (ARLs) with advanced 
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diagnostic facilities for backup support and serotyping of dengue samples. 
For details, please refer to NVBDCP website www.nvbdcp.gov.in. 
–These laboratories receive the samples, diagnose and send the 
report (line list) regularly to districts/municipal health authorities for 
implementation of preventive measures to interrupt the transmission. 
–NS1 antigen tests – GoI introduced ELISA-based NS1 antigen test 
in 2010 in addition to MAC-ELISA tests which can detect the case during 
day 1 to day 5 of illness. 
RECOMMENDATIONS FOR TREATMENT 
Group A – patients who may be sent home (see the home 
care card for dengue in Textbox G) 
These are patients who are able to tolerate adequate volumes of 
oral fluids and pass urine at least once every six hours, and do not 
have any of the warning signs, particularly when fever subsides. 
Ambulatory patients should be reviewed daily for disease 
progression (decreasing white blood cell count, defervescence and 
warning signs) until they are out of the critical period. Those with 
stable haematocrit can be sent home after being advised to return 
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to the hospital immediately if they develop any of the warning 
signs and to adhere to the following action plan: 
• Encourage oral intake of oral rehydration solution 
(ORS), fruit juice and other fluids containing 
electrolytes and sugar to replace losses from fever 
and vomiting. Adequate oral fluid intake may be 
able to reduce the number of hospitalizations (13). 
[Caution: fluids containing sugar/glucose may 
exacerbate hyperglycaemia of physiological stress 
from dengue and diabetes mellitus.] 
• Give paracetamol for high fever if the patient is 
uncomfortable. The interval of paracetamol dosing 
should not be less than six hours. Tepid sponge if the 
patient still has high fever. Do not give 
acetylsalicylic acid (aspirin), ibuprofen or other non-
steroidal anti-inflammatory agents (NSAIDs) as 
these drugs may aggravate gastritis or bleeding. 
Acetylsalicylic acid (aspirin) may be associated with 
Reye’s Syndrome. 
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• Instruct the care-givers that the patient should be 
brought to hospital immediately if any of the 
following occur: no clinical improvement, 
deterioration around the time of defervescence, 
severe abdominal pain, persistent vomiting, cold and 
clammy extremities, lethargy or 
irritability/restlessness, bleeding (e.g. black stools or 
coffee-ground vomiting), not passing urine for more 
than 4–6 hours. 
Patients who are sent home should be monitored daily by health 
care providers for temperature pattern, volume of fluid intake and 
losses, urine output (volume and frequency), warning signs, signs 
of plasma leakage and bleeding, haematocrit, and white blood cell 
and platelet counts (see group B). 
Group B – patients who should be referred for in-
hospital management 
Patients may need to be admitted to a secondary health care 
centre for close observation, particularly as they approach the 
critical phase. These include patients with warning signs, those 
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with co-existing conditions that may make dengue or its 
management more complicated (such as pregnancy, infancy, old 
age, obesity, diabetes mellitus, renal failure, chronic haemolytic 
diseases), and those with certain social circumstances (such as 
living alone, or living far from a health facility without reliable 
means of transport). 
• Obtain a reference haematocrit before fluid therapy. Give only 
isotonic solutions such as 0.9% saline, Ringer’s lactate, or 
Hartmann’s solution. Start with 5–7 ml/ kg/hour for 1–2 hours, 
then reduce to 3–5 ml/kg/hr for 2–4 hours, and then reduce to 2–
3 ml/kg/hr or less according to the clinical response (Textboxes 
H, J and K). 
• Reassess the clinical status and repeat the haematocrit. If the 
haematocrit remains the same or rises only minimally, continue 
with the same rate (2–3 ml/kg/hr) for another 2–4 hours. If the 
vital signs are worsening and haematocrit is rising rapidly, 
increase the rate to 5–10 ml/kg/hour for 1–2 hours. Reassess the 
clinical status, repeat the haematocrit and review fluid infusion 
rates  
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• 2) Give the minimum intravenous fluid volume required to 
maintain good perfusion and urine output of about 0.5 ml/kg/hr. 
Intravenous fluids are usually needed for only 24–48 hours. 
Reduce intravenous fluids gradually when the rate of plasma 
leakage decreases towards the end of the critical phase. This is 
indicated by urine output and/or oral fluid intake that is/are 
adequate, or haematocrit decreasing below the baseline value in 
a stable patient. 
• Patients with warning signs should be monitored by health care 
providers until the period of risk is over. A detailed fluid balance 
should be maintained. Parameters that should be monitored 
include vital signs and peripheral perfusion (1–4 hourly until the 
patient is out of the critical phase), urine output (4–6 hourly), 
haematocrit (before and after fluid replacement, then 6–12 
hourly), blood glucose, and other organ functions (such as renal 
profile, liver profile, coagulation profile, as indicated). 
 Group C – patients who require emergency treatment and urgent 
referral when they have severe dengue 
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Patients require emergency treatment and urgent referral when they are 
in the critical phase of disease, i.e. when they have: 
– severe plasma leakage leading to dengue shock and/or fluid 
accumulation with respiratory distress; 
– severe haemorrhages; 
– severe organ impairment (hepatic damage, renal 
impairment, cardiomyopathy, encephalopathy or 
encephalitis).causes such as essential thrombocytosis, 
polycythemia vera, protein C and S deficiency. 
–  Start intravenous fluid resuscitation with isotonic crystalloid 
solutions at 5–10 ml/kg/hour over one hour. Then reassess 
the patient’s condition (vital signs, capillary refill time, 
haematocrit, urine output). The next steps depend on the 
situation. 
– If the patient’s condition improves, intravenous fluids should 
be gradually reduced to 5–7 ml/kg/hr for 1–2 hours, then to 
3–5 ml/kg/hr for 2–4 hours, then to 2–3 ml/kg/hr, and then 
further depending on haemodynamic status, which can be 
maintained for up to 24–48 hours. (See textboxes H and J for 
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a more appropriate estimate of the normal maintenance 
requirement based on ideal body weight). 
– If vital signs are still unstable (i.e. shock persists), check the 
haematocrit after the first bolus. If the haematocrit increases 
or is still high (>50%), repeat a second bolus of crystalloid 
solution at 10–20 ml/kg/hr for one hour. After this second 
bolus, if there is improvement, reduce the rate to 7–10 ml/ 
kg/hr for 1–2 hours, and then continue to reduce as above. If 
haematocrit decreases compared to the initial reference 
haematocrit (<40% in children and adult females, <45% in 
adult males), this indicates bleeding and the need to cross-
match and transfuse blood as soon as possible (see treatment 
for haemorrhagic complications). 
– Further boluses of crystalloid or colloidal solutions may need 
to be give 
Treatment of complications and other areas of treatment 
Fluid overload with large pleural effusions and ascites is a 
common cause of acute respiratory distress and failure in severe 
dengue. Other causes of respiratory distress include acute pulmonary 
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oedema, severe metabolic acidosis from severe shock, and Acute 
Respiratory Distress Syndrome (ARDS) (refer to standard textbook of 
clinical care for further guidance on management). 
Causes of fluid overload are: 
– excessive and/or too rapid intravenous fluids; 
– incorrect use of hypotonic rather than isotonic crystalloid 
solutions; 
– inappropriate use of large volumes of intravenous fluids in 
patients with unrecognized severe bleeding; 
– inappropriate transfusion of fresh-frozen plasma, platelet 
concentrates and cryoprecipitates; 
– continuation of intravenous fluids after plasma leakage has 
resolved (24–48 hours from defervescence); 
– co-morbid conditions such as congenital or ischaemic 
heart disease, chronic lung and renal diseases. 
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.Early clinical features of fluid overload are: 
– respiratory distress, difficulty in breathing; 
– rapid breathing; 
– chest wall in-drawing; 
– wheezing (rather than crepitations); 
– large pleural effusions; 
– tense ascites; 
– increased jugular venous pressure (JVP). 
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Late clinical features are: 
– pulmonary oedema (cough with pink or frothy sputum ± 
crepitations, cyanosis); 
– irreversible shock (heart failure, often in combination with 
ongoing hypovolaemia). 
Additional investigations are: 
– the chest x-ray which shows cardiomegaly, pleural 
effusion, upward displacement of the diaphragm by the ascites 
and varying degrees of “bat’s wings” appearance ± Kerley B 
lines suggestive of fluid overload and pulmonary oedema; 
– ECG to exclude ischaemic changes and arrhythmia; 
– arterial blood gases; 
– echocardiogram for assessment of left ventricular 
function, dimensions and  regional wall dyskinesia that may 
suggest underlying ischaemic heart disease; 
– cardiac enzymes.even before ascites may develop. 
The action plan for the treatment of fluid overload is as follows: 
• Oxygen therapy should be given immediately. 
• Stopping intravenous fluid therapy during the recovery 
phase will allow fluid in the pleural and peritoneal cavities 
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to return to the intravascular compartment. This results in 
diuresis and resolution of pleural effusion and ascites. 
Recognizing when to decrease or stop intravenous fluids is 
key to preventing fluid overload. When the following signs 
are present, intravenous fluids should be discontinued or 
reduced to the minimum rate necessary to maintain 
euglycaemia: 
– signs of cessation of plasma leakage; 
– stable blood pressure, pulse and peripheral perfusion; 
– haematocrit decreases in the presence of a good pulse 
volume; 
– afebrile for more than 24–48 days (without the use of 
antipyretics); 
– resolving bowel/abdominal symptoms; 
– improving urine output. 
• The management of fluid overload varies according to the 
phase of the disease and the patient’s haemodynamic status. 
If the patient has stable haemodynamic status and is out of 
the critical phase (more than 24–48 hours of defervescence), 
stop intravenous fluids but continue close monitoring. If 
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necessary, give oral or intravenous furosemide 0.1–0.5 
mg/kg/dose once or twice daily, or a continuous infusion of 
furosemide 0.1 mg/kg/hour. Monitor serum potassium and 
correct the ensuing hypokalaemia. 
• If the patient has stable haemodynamic status but is still 
within the critical phase, reduce the intravenous fluid 
accordingly. Avoid diuretics during the plasma leakage 
phase because they may lead to intravascular volume 
depletion. 
• Patients who remain in shock with low or normal 
haematocrit levels but show signs of fluid overload may 
have occult haemorrhage. Further infusion of large volumes 
of intravenous fluids will lead only to a poor outcome. 
Careful fresh whole blood transfusion should be initiated as 
soon as possible. If the patient remains in shock and the 
haematocrit is elevated, repeated small boluses of a colloid 
solution may help. 
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Coagulation Cascade  
1. “Primary haemostasis( vasoconstriction and platelet 
                 plug formation) 
2. Secondary haemostasis (activation of coagulation 
                   factors and generation of thrombin) 
3. Fibrin clot formation and stabilization 
4. Inhibition of coagulation (inhibition of thrombin generation and 
fibrin clot breakdown) 
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The prothrombin time (PT) measures the integrity of extrinsic and 
common pathways of coagulation (factors VII, X and V; prothrombin and 
fibrinogen). The activated partial thromboplastin time (aPTT) measures the 
integrity of the intrinsic and common pathways of coagulation (high 
molecular weight kininogen; prekallikrein; factors XII, XI, IX, VIII, X and 
V; prothrombin and fibrinogen). The sensitivity of the PT and aPTT in 
detecting coagulation factors deficiencies may vary with the reagent used 
to perform these tests, and each laboratory must determine its own 
reference standards. The thrombin time (TT) is a screen for quantitative 
deficiencies and qualitative defects of plasma fibrinogen. 
Thromboelastography (TEG) assesses the viscoelastic properties of 
blood samples under low shear conditions. It measures the clot’s physical 
property by using a stationary cylindrical cup that hold the blood sample 
and oscillates through an angle of 4o45 with each rotation cycle lasting 10 
sec. Besides standard TEG, Platelet Mapping which is an extension of TEG 
technology, in addition to providing information on clot formation and 
lyses of whole blood sample, it quantifies the contribution of fibrin, 
adenosine diphosphate (ADP) receptor and thromboxane A2 (Tx A2) 
receptor in clot  
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Prothrombin Time (PT) 
Principle: The prothrombin time test belongs to a group of blood tests 
that assess the clotting ability of blood.4, 5 The test is also known as the 
pro time or PT test. The blood is collected in a tube that contains sodium 
citrate to prevent the clotting process from starting before the test. The 
blood cells are separated from the liquid part of blood (plasma). The PT 
test is performed by adding the patient’s plasma to a protein in the blood 
(thromboplastin) that converts prothrombin to thrombin. The mixture is 
then kept in a warm water bath at 37°C for one to two minutes. Calcium 
chloride is added to the mixture in order to counteract the Sodium citrate 
and allow clotting to proceed. The test is timed from the addition of the 
calcium chloride until the plasma clots. This time is called as the 
prothrombin time. 
Normal value : The normal prothrombin time is 11-15 seconds. A 
prothrombin time within this range indicates that the patient has normal 
amounts of clotting factors VII and X. A prolonged PT time is considered 
abnormal. 
Abnormal value: The prothrombin time will be prolonged if the 
concentration of any of the tested factors is 10% or more below normal 
plasma values. A prolonged prothrombin time indicates a deficiency in any 
of factors VII, X, V, prothrombin, or fibrinogen. It may mean that the 
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patient has a vitamin K deficiency, a liver disease, or disseminated 
intravascular coagulation (DIC). The prothrombin time of patients 
receiving warfarin therapy will also be prolonged-usually in the range of 
one and one half to two times the normal PT time. PT time that exceeds 
approximately two and a half times the control value (usually 30 seconds 
or longer) is ground for concern, as abnormal bleeding may occur. 
Limitations: Spurious results may occur if the blood to 
anticoagulant ratio is not 9:1. The PT clotting times may be prolonged by 
substances including corticosteroids, EDTA, oral contraceptives, 
asparaginase, clofibrate, erythromycin, ethanol, Tetracycline and 
anticoagulants such as heparin and coumarin. The PT may be shortened by 
substances including antihistamines, butabarbital 
Activated Partial Thromboplastin Time (APTT) 
Principle : APTT is the time required for plasma to be clotted when 
maximal surface contact activation and optimal phospholipid and calcium 
concentration are provided. 
Results are expressed as time seconds or as ratio. 
Normal range: Every laboratory should determine its own normal 
range. In our laboratory with commercial reagents it is 29-35 seconds. 
Interpretation : APTT is sensitive to the deficiencies or abnormalities of 
both intrinsic and common coagulation factors i.e. Factors I, II, V, X, VIII, 
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IX, XI, XII, Fletcher factor and Fitzgerald factor. The test is more sensitive 
to an abnormality occurring in the early stage of coagulation mechanism 
i.e. factors leading upto the generation of Factor Xa and less sensitive to 
later stage i.e. Factor II fibrinogen. A deficiency levels < 20-50% of Factor 
XII, XI, IX, XIII, X or V would give prolonged APTT. Where as a 
deficiency upto 10% of Prothrombin and 0.5-1g / litre of fibrinogen or less 
would give an abnormal APTT. 
APTT is also prolonged when there is an inhibitor present in patient’s 
plasma. Therefore whenever a prolonged APTT is detected, screening test 
for inhibitor must be performed. It is also an important test for the control 
of heparin therapy. Therapeutic range-60-100 seconds. 
APTT Mixing Study with normal serum / adsorbed plasma 
Principle: Plasma samples found to have a prolonged APTT are 
further investigated to define the abnormality by performing mixing or 
correction tests. Correction of the abnormality by the additive indicates 
that the reagent must contain the substance deficient in the test sample. 
An abnormal APTT is repeated on 50:50 mixtures of a known 
congenitally deficient plasma and the test plasma, or on 50:50 mixtures 
of aged / adsorbed plasma and test plasma until correction is obtained and 
the missing factor identified. 
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MILD, MODERATE AND SEVERE ELEVATIONS OF 
AMINOTRANSFERASES 
1. Severe ( > 20 times, 1000 U/L) : The AST and ALT levels are 
increased to some extent in almost all liver diseases. The highest 
elevations occur in severe viral hepatitis, drug or toxin induced 
hepatic necrosis and circulatory shock. Although enzyme levels may 
reflect the extent of hepatocellular necrosis they do not correlate with 
eventual outcome. In fact declining AST and ALT may indicate 
either recovery of poor prognosis in fulminant hepatic failure.4, 5 
2. Moderate (3-20 times): The AST and ALT are moderately elevated 
in acute hepatitis, neonatal hepatitis, chronic hepatitis, autoimmune 
hepatitis, drug induced hepatitis, alcoholic hepatitis and acute biliary 
tract obstructions. The ALT is usually more frequently increased as 
compared to AST except in chronic liver disease. In uncomplicated 
acute viral hepatitis, the very high initial levels approach normal 
levels within 5 weeks of onset of illness and normal levels are 
obtained in 8 weeks in 75% of cases. 
For reasons, which are not, understood AST levels appear 
disproportionately low in patients with Wilson disease.4,5 
3. Mild (1-3 times) : These elevations are usually seen in sepsis 
induced neonatal hepatitis, extrahepatic biliary atresia (EHBA), 
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fatty liver, cirrhosis, non alcoholic steato hepatitis(NASH), drug 
toxicity, myositis, duchenne muscular dystrophy and even after 
vigorous exercise.1,4 
One third to one half of healthy individuals with an isolated 
elevation of ALT on repeated testing have been found to be 
normal.13 
AST: ALT ratio 
The ratio of AST to ALT is of use in Wilson disease, CLD and 
alcoholic liver disease and a ratio of more than 2 is usually observed. The 
lack of ALT rise is probably due to pyridoxine deficiency. In NASH the 
ratio is less than one in the absence of fibrosis on liver biopsy.4 
In viral hepatitis the ratio is usually less than one. The ratio 
invariably rises to more than one as cirrhosis develops possibly because 
of reduced plasma clearance of AST secondary to impaired function of 
sinusoidal cells.14 
ALT exceeds AST in toxic hepatitis, viral hepatitis, chronic active 
hepatitis and cholestatic hepatitis 5 
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Biochemical Patterns of Liver Involvement in Dengue Virus Infections 
 
Multiple investigators have documented elevated serum liver 
enzymes with dengue infections, particularly the transaminases Aspartate 
Transaminase (AST) and Alanine Transaminase (ALT). Kuo et al. 
published a series of 270 dengue patients and found elevated ALT and AST 
levels in 82% and 93%, respectively [9]. Most AST and ALT elevations 
were mild to moderate but elevations greater than ten times the upper limit 
of normal were seen in 11.1% and 7.4%, respectively. In a study of 169 
serologically confirmed dengue cases in Rio de Janeiro, Brazil, 65.1% 
(110/169) had abnormal aminotransferases [17].  
During acute infections, it is often not possible to do a liver biopsy 
due to thrombocytopenia, coagulation disturbances and/or the presence of 
ascites. Therefore, most of the published histological data on dengue-
associated liver dysfunction comes from autopsy specimens. As a result, 
these data are skewed towards the more severe end of the disease spectrum. 
Histologic patterns of liver disease in milder cases are not clear. The 
available histologic data describe hepatocellular necrosis, apoptosis-
induced Councilman Bodies, steatosis, and inflammatory cell infiltrates. 
Hepatocellular necrosis seen in dengue affects the midzonal and 
centrilobular areas of the hepatic acinus, which are the area’s most 
susceptible to anoxia. Fatal Dengue Hemorrhagic Fever (DHF) autopsy 
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findings are characterized by the presence of variable degrees of 
hepatocyte necrosis, primarily midzonal. Data on the ability of elevated 
aminotransferase levels to predict dengue infection severity are conflicting. 
In a study of 690 dengue patients from Singapore, AST or ALT levels did 
not discriminate between DF and DHF or between non-severe and severe 
dengue [18]. However, median AST and ALT levels were significantly 
higher with increasing dengue severity by both 1997 and 2009 WHO 
criteria. Prakash et al. published a series of 699 dengue patients from 
Karachi, Pakistan [26]. In this study, the overall mortality was 33% in the 
mild to moderate hepatitis group and 67% in the severe hepatitis group 
(p<0.002). Severe hepatitis, defined as an ALT level greater than 300 IU/L, 
was associated with prolonged length of hospital stay, mortality, bleeding, 
and renal failure. 
Aptt prolongation in dengue 
Recently it has shown that non-structural protein 1 (NS1) of dengue 
virus can bind both to thrombin and pro thrombin. Binding to thrombin 
will not make any changes whereas pro thrombin activation is inhibited. 
This can explain changes in aPTT occur early before antibodies are 
formed.3,4 NS1 also contribute plasma leakage by producing endothelial 
changes independent of immunological mechanism.5,6 During acute phase 
of dengue lot of inflammatory mediators and cytokines are released. 
Complements like C3a C5a IL6, IL10, TNF α interferon ∞and histamine 
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leading to plasma leakage, thrombocytopenia, and decrease in fibrinogen 
coagulation factors. In addition, the inflammation hepatocytes leading to 
increase in AST, ALT. Damage to liver cells further decreases the 
coagulation factor synthesis this can alter the PT APTT, systems. Various 
studies have shown the participation of DV in the down regulation of the 
thrombomodulin-thrombin-protein C complex formation at the endothelial 
surface, with a reduction in activated protein C (APC). APC is the most 
important vasoprotective protein because it down regulates thrombin 
generation (by the inactivation of procoagulant factors Va and VIIIa) and 
has anti-inflammatory, ant apoptotic, and barrier protection properties. 
These biological functions of APC are associated with the endothelial 
protein C receptor (EPCR) and protease-activated receptor 1 (PAR-1) 
signalling pathways, which link the coagulation-inflammation responses. 
Alterations in the antithrombotic and cyto protective protein C pathways 
during DV infection of human endothelial vascular cells have been 
observed, which may explain the vasculopathy observed during DHF 
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MATERIALS AND METHODS 
STUDY POPULATION: 
The study will be conducted on  100 dengue  patients admitted 
to GRH , Madurai during the study period of 12 months  
INCLUSION CRITERIA: 
• Patients presenting with fever from a dengue endemic       
•    H/o headache , joint pain , nause , vomiting  
•   lab confirmed dengue  
•   positive tourniquet test 
EXCLUSION CRITERIA:  
• Patients with bleeding diathesis . 
•    Patients on  Anticoagulant therapy . 
•    Alcoholics . 
•    CLD patients  
DATA COLLECTION: 
A previously designed proforma was used to collect the 
demographic and clinical details of the patients.  All the patients  
underwent  detailed clinical evaluation, appropriate investigations,  
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STUDY PROTOCOL: 
DESIGN OF STUDY: 
• Prospective study 
PERIOD OF STUDY: 
May  2018 To December2018 ( 8 months) 
METHODOLOGY: 
History was taken on details and duration of fever from a dengue 
endemic      H/o headache , joint pain , nause was noted . Platelet count, 
prothrombin time and INR,liver function tests including serum 
bilirubin, serum transaminases, serum albumin was estimated. 
 LABORATORY INVESTIGATIONS: 
                             Platelet count,liver function tests including serum 
bilirubin, albumin,globulin,transaminases, prothrombin time  activated 
partial thromboplastin time and INR.  
COLLABORATING DEPARTMENTS: 
Department Of  Medical Gastroenterology 
Department Of  Biochemistry 
Department of  Radiology 
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ETHICAL CLEARANCE: Clearance obtained 
CONSENT: Individual written and informed consent obtained. 
STATISTICAL ANALYSIS:  
All data were entered in Excel 2007 and statistical analysis was 
performed using the statistical software SPSS 16.0.Data were expressed 
as frequency (with percentages), median values (with range (min, 
max)). For continuous variables, Mann Whitney U-test was performed 
to find the differences between two groups and for categorical variables 
Pearson’s chi-square test was performed.Results were defined as 
statistically significant when the P value (2-sided) was less than 0.05 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  SELF 
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RESULTS AND OBSERVATIONS 
1) Age distribution :  
AGE No. of cases 
< 20 8 
20 – 40 81 
> 40 11 
Total 100 
 
 
Comments : dengue is prevalent among middle age group 
individuals 
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2) Gender distribution: 
GENDER No. of cases 
Male 23 
Female 77 
Total 100 
 
 
 
 
 
23
77
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3) Percentage of secondary dengue : 
IGG No. of cases 
Positive 36 
Negative 64 
Total 100 
 
 
Comments: out of 100 Dengue  patients 36 were of secondary 
dengue  
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4) Dengue haemorrhagic fever incidence: 
DHF No. of cases 
Yes 18 
No 82 
Total 100 
 
 
Comments: out  of 100 Dengue patients 18 went to develop 
Dengue Haemorrhagic fever . 
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5) Mean platelet on day 1 in DHF vs dengue: 
DHF vs PLT D1 Mean S.D p' value  
Yes (18) 27388.9 6954.8   
No (82) 78853.7 12639.5 <0.001 Significant 
 
 
Comments : The patients in the DHF side had lower platelet 
counts when compared to the Dengue fever wing on Day 1 . 
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6) SGPT in DHF vs Dengue fever 
DHF vs SGPT Mean S.D p' value  
Yes (18) 322.17 180.71   
No (82) 75.50 86.90 
<0.001 
Significant 
   
 
 
Comments :  There is  statistically significant elevation of SGPT 
in DHF 
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7) SGOT in DHF vs Dengue fever: 
DHF vs SGOT Mean S.D p' value   
Yes (18) 587.4 276.9     
No (82) 113.3 108.8 <0.001 Significant 
 
 
Comments : There  is significant elevation of SGOT in DHF 
patients . there is significant elevation of SGOT when compared 
to SGPT  
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9) aPTT in DHF vs Dengue fever:  
DHF vs Aptt Mean S.D p' value   
Yes (18) 45.22 7.08     
No (82) 33.44 3.30 <0.001 Significant 
 
 
Comments : Statistically significant elevation of aPTT among 
DHF patients when compared to dengue fever patients  
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10) INR in DHF vs Dengue : 
DHF vs INR Mean S.D p' value   
Yes (18) 1.61 0.39     
No (82) 0.99 0.22 <0.001 Significant 
 
 
Comments : INR elevation also corresponds to the severity of 
dengue but doesn’t correlate with the aPTT values hence can not 
be statistically significant  
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DISCUSSION 
 Our study was done to assess the usefulness of aPTT in predictin th 
severity of dengue in a tertiary hospital in Madurai 
 Among the dengue patients there were 81 patients in 20 to 40 age 
group 11 patients were more than 40 ,  8 patients were less than 20 
years of age  
 Among the gender predilection , females were affected more than 
males  
 Secondary dengue was found to involve about 36 patients 36 percent 
had IgG positivity  
 Among the dengue fever patients 18 patients had dengue 
haemorrhagic fever and developed complications and were needing 
treatment  
 The mean platelet count among dengue fever patients were 76,300 
And the mean platelet count among the patients with dengue 
haemorrhage fever was 27,000 
The average platelet count fall occurred during the 4th day and was 
more severe among the dengue haemorrhagic fever patients  
 The average SGOT in dengue haemorrhagic fever patients was 587 
and among dengue fever patietns was 113 . there was statistically 
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significant elevation . dengue haemorrhagic fever patients had a 
higher SGOT whn compared to the Dengue fever patients 
 The average SGPT in dengue haemorrhagic fever patients was 322 
and among dengue fever patietns was 75 . there was statistically 
significant elevation . dengue haemorrhagic fever patients had a 
higher SGPT whn compared to the Dengue fever patients but not as 
statisticall significan as SGOT 
 The average PT in dengue haemorrhagic fever patients was 17.8 and 
among dengue fever patietns was 12.4 . there was statistically 
significant elevation . dengue haemorrhagic fever patients had a 
higher prothrombin time whn compared to the Dengue fever patients 
 The average INR in dengue haemorrhagic fever patients was 1.61 
and among dengue fever patietns was 0.99. there was statistically 
significant elevation . dengue haemorrhagic fever patients had a 
higher SGOT whn compared to the Dengue fever patients 
 The average aPTT  in dengue haemorrhagic fever patients was 45.22 
and among dengue fever patietns was 33.2 . there was statistically 
significant elevation . dengue haemorrhagic fever patients had a 
higher aPTT whn compared to the Dengue fever patients 
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SUMMARY 
 
Dengue is a dangerous infectious disease threatening the general 
population and the particularly viable population . the most feared 
complications of dengue are due to the secondary effusions and the fluid 
leakage . The most dreaded complication Dengue Haemorrhagic fever 
which is easily detectable by the ominous presence of fluid leakage and fall 
in platelet count and elea=vation in PCV due to hemoconcentration . There 
is need for firther easy bed side tests to detect the development of Dengue 
Haemorrhagic fever among Dengue patients . Our study focused on the 
involvement of liver enzymes and aPTT in dengue haemorrhagic fever . 
There is a statistically significant elevation of SGOT and SGPT among 
patients with DHF , More than that there is a significant elevation of aPTT 
among patients with Dengue Haremorrhagic fever . This can be utilized as 
a good tool in detecting the patients who might land up in dengue 
Haemorrhagic fever. This can be anticipated and adequate fluid 
resuscitation and timely initiation of platelet transfusion prevent serious 
adverse outcomes . 
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Thus, this study emphasizes on the role of coagulation in the 
pathogenesis and prognostication in severe dengue The APTT 
prolongation occurs even before immunological changes starts. It can 
predict patients likely to develop complications. This simple cheaper blood 
investigation of other coagulation function PT, INR, and liver enzymes, 
can be used as a supporting evidence for severe dengue and thus helps in 
early intervention and management which can reduce the mortality of 
dengue fever. 
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CONCLUSION 
 
1) SGOT and SGPT elevation proved to be an early predictor in the 
progression of Dengue fever to Dengue Haemorrhagic fever 
2) aPTT prolongation proved to be an even early predictor in the 
progression of Dengue to Dengue haemorrhagic fever and hence 
rapid intervention prevented the dreaded complications of dengue . 
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PROFORMA 
Name: 
Age / Sex: 
IP no: 
Occupation: 
 
Presenting complaints: 
h/o,fever , joint pain , myalgia , bleeding diathesis ,  diarrhoea , 
retroorbital pain.  
 
Past History: 
h/o bleeding diathesis , liver disease , kidney disease ,  
h/o previous infection with dengue 
h/o,HEPATITIS.  
 
Personal history 
alcoholic/ non alcoholic 
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smoker/ nonsmoker 
Clinical Examination: 
General Examination: 
Consciousness, orientation, febrile/afebrile, Pallor, jaundice, Clubbing, 
Lymphadenopathy, pedal edema. 
Vitals: 
PR 
BP 
RR 
SpO2 
Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
Laboratory investigations: 
1.platelet count 
2.LFTs including serum bilirubin,albumin,globulin,transaminases,    
3. prothrombin time  aPtt  and INR. 
 
Diagnosis 
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LIST OF ABBREVIATION 
 
LFT - liver function test 
AST - Aspartate aminotransferase 
ALT - Alanine aminotransferase 
PT - prothrombin time 
aptt -  Activated partial thromboplastin time  
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